- Home
- YQ vs BRTX Comparison
YQ vs BRTX Comparison
Compare YQ & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- BRTX
- Stock Information
- Founded
- YQ 2012
- BRTX 1997
- Country
- YQ China
- BRTX United States
- Employees
- YQ N/A
- BRTX N/A
- Industry
- YQ Other Consumer Services
- BRTX Managed Health Care
- Sector
- YQ Real Estate
- BRTX Health Care
- Exchange
- YQ Nasdaq
- BRTX Nasdaq
- Market Cap
- YQ 14.9M
- BRTX 10.7M
- IPO Year
- YQ 2020
- BRTX N/A
- Fundamental
- Price
- YQ $1.95
- BRTX $1.54
- Analyst Decision
- YQ
- BRTX Strong Buy
- Analyst Count
- YQ 0
- BRTX 1
- Target Price
- YQ N/A
- BRTX $18.00
- AVG Volume (30 Days)
- YQ 8.3K
- BRTX 1.1M
- Earning Date
- YQ 03-19-2025
- BRTX 03-28-2025
- Dividend Yield
- YQ N/A
- BRTX N/A
- EPS Growth
- YQ N/A
- BRTX N/A
- EPS
- YQ N/A
- BRTX N/A
- Revenue
- YQ $28,507,378.00
- BRTX $377,000.00
- Revenue This Year
- YQ N/A
- BRTX $482.76
- Revenue Next Year
- YQ N/A
- BRTX $212.24
- P/E Ratio
- YQ N/A
- BRTX N/A
- Revenue Growth
- YQ 22.55
- BRTX 189.55
- 52 Week Low
- YQ $1.50
- BRTX $1.03
- 52 Week High
- YQ $3.20
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- YQ 52.46
- BRTX 39.03
- Support Level
- YQ $1.86
- BRTX $1.46
- Resistance Level
- YQ $2.04
- BRTX $1.64
- Average True Range (ATR)
- YQ 0.06
- BRTX 0.26
- MACD
- YQ -0.01
- BRTX -0.04
- Stochastic Oscillator
- YQ 37.50
- BRTX 18.45
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.